Viewing Study NCT06781450

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2026-02-02 @ 12:00 PM
Study NCT ID: NCT06781450
Status: RECRUITING
Last Update Posted: 2025-01-30
First Post: 2024-12-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Mediastinal B Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pembrolizumab View
None nivolumab View
None brentuximab vedotin View